FDA Peptide Update: Category 2 Removals Explained Orthopedic Use of BPC 157 Sports Med Review Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA mulls compounding for peptides previously flagged over safety risks BioSpace The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA's new guidelines on bulk drug compounding Pharmacy & Healthcare Legal Blog